EU Group Wants Greater Reciprocity As Chinese Foreign Deals Expand
Ahead of last weekend’s G20 meeting in Hangzhou, a powerful EU business group in China called for increased reciprocity over major M&A deals, suggesting that closer European scrutiny may come if China does not further open its doors. Drug price pressures in China were also flagged up as a major European concern in a new position paper.
You may also be interested in...
All eyes on a list of selected oral hepatitis C drugs that are expected to win out in China's notoriously lengthy approval battle, amid a potentially huge opening as Chinese HCV patients switch from interferon to all oral therapies.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.